Literature DB >> 9149069

Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities.

E Lebovics1, F Seif, D Kim, A Elhosseiny, B M Dworkin, A Casellas, S Clark, W S Rosenthal.   

Abstract

Pruritus is a common symptom of chronic cholestatic liver diseases but is considered rare in chronic hepatitis. We observed pruritus to be an unusually common complaint in patients with advanced chronic hepatitis C. We reviewed the records of 175 chronic hepatitis C patients to identify patients with severe, diffuse, unexplained pruritus; 12 consecutive prospective patients undergoing liver biopsy for chronic hepatitis C served as controls. Assessment included laboratory biochemical tests and assessment of liver pathology by stage, grade, hepatic activity index, and a bile duct score. Pruritus was present in nine (5.1%) patients. Serum AST, ALT, alkaline phosphatase, GGTP, total bilirubin, and ferritin were similar in pruritics and controls. Pruritics had higher serum bile acids (2028.4 +/- 223.1 mmol/liter vs 423.1 +/- 194.3, P < 0.001), higher transferrin saturation (57.5 +/- 6.8% vs 33.2 +/- 3.3, P < 0.01), and lower HCV RNA by bDNA (24.5 +/- 12.7 x 10(5) vs 172.7 +/- 54.1 x 10(5), P < 0.05). Pathology revealed cirrhosis in 6/9 (66.6%) pruritics vs 1/12 (8.3%) controls (P < 0.01). Pruritics had higher pathologic stage (3.7 +/- 0.2 vs 2.2 +/- 0.4, P < 0.01), grade (4.4 +/- 0.2 vs 2.1 +/- 0.2, P < 0.001), activity index (14.3 +/- 1.9 vs 8.6 +/- 1.9, P < 0.025), and bile duct score (7.6 +/- 0.6 vs 4.7 +/- 0.4, P < 0.01). Of eight pruritics treated with IFN-alpha2b, two had complete ALT response and one relapsed. Pruritus followed a relapsing course and only three patients partially responded despite a variety of interventions. In conclusion, pruritus is a common complication of advanced CHC. Its presence is associated with high serum bile acids, advanced pathology and bile duct abnormalities. The clinical course of pruritus is relapsing and response to therapy is inconsistent. These features suggest that pruritus in CHC has a pathogenesis that may vary from that of chronic cholestatic diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149069     DOI: 10.1023/a:1018865809556

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

Review 1.  Management of the pruritus of cholestasis: potential role of opiate antagonists.

Authors:  N V Bergasa; E A Jones
Journal:  Am J Gastroenterol       Date:  1991-10       Impact factor: 10.864

2.  Measurements of iron status in patients with chronic hepatitis.

Authors:  A M Di Bisceglie; C A Axiotis; J H Hoofnagle; B R Bacon
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

Review 3.  Liver transplantation: an overview.

Authors:  W C Maddrey; D H Van Thiel
Journal:  Hepatology       Date:  1988 Jul-Aug       Impact factor: 17.425

4.  Intracellular localization of polymerase chain reaction (PCR)-amplified hepatitis C cDNA.

Authors:  G J Nuovo; K Lidonnici; P MacConnell; B Lane
Journal:  Am J Surg Pathol       Date:  1993-07       Impact factor: 6.394

5.  Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.

Authors:  N V Bergasa; D W Alling; T L Talbot; M G Swain; C Yurdaydin; M L Turner; J M Schmitt; E C Walker; E A Jones
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

6.  Pruritus as a symptom of hepatitis C.

Authors:  D A Fisher; T L Wright
Journal:  J Am Acad Dermatol       Date:  1994-04       Impact factor: 11.527

7.  Hepatitic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies.

Authors:  K Kaji; Y Nakanuma; M Sasaki; M Unoura; K Kobayashi; A Nonomura; K Tsuneyama; J Van de Water; M E Gershwin
Journal:  Mod Pathol       Date:  1994-12       Impact factor: 7.842

8.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  J H Lefkowitch; E R Schiff; G L Davis; R P Perrillo; K Lindsay; H C Bodenheimer; L A Balart; T J Ortego; J Payne; J L Dienstag
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Itch in liver disease: facts and speculations.

Authors:  C N Ghent; J R Bloomer
Journal:  Yale J Biol Med       Date:  1979 Jan-Feb
View more
  9 in total

1.  Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage.

Authors:  E Giannini; F Botta; A Fasoli; P Romagnoli; L Mastracci; P Ceppa; I Comino; A Pasini; D Risso; R Testa
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

2.  Cholestatic presentation of chronic hepatitis C: a clinical and histological study with a review of the literature.

Authors:  K S Kumar; M H Saboorian; W M Lee
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

3.  Study of pruritus in chronic hepatitis C patients.

Authors:  Kazuyoshi Suzuki; Masaya Tamano; Yasumi Katayama; Toru Kuniyoshi; Kagemasa Kagawa; Hiroshi Takada; Kazutomo Suzuki
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

4.  A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease.

Authors:  P Sorrentino; G Tarantino; A Perrella; P Micheli; O Perrella; P Conca
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

Review 5.  Pruritus in chronic liver disease: mechanisms and treatment.

Authors:  Nora V Bergasa
Journal:  Curr Gastroenterol Rep       Date:  2004-02

6.  Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.

Authors:  Monika Rau; Johannes Schmitt; Thomas Berg; Andreas E Kremer; Bruno Stieger; Katharina Spanaus; Bertram Bengsch; Marta R Romero; Jose J Marin; Verena Keitel; Hartwig Klinker; Hans-Peter Tony; Beat Müllhaupt; Andreas Geier
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

7.  Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus.

Authors:  Hiroshi Yoshitani; Junko Ito; Hideki Kozono
Journal:  Hepat Med       Date:  2022-05-02

Review 8.  Host genetic variants in the pathogenesis of hepatitis C.

Authors:  Monika Rau; Katharina Baur; Andreas Geier
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

9.  Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.

Authors:  Hatsue Fujino; Mio Tanaka; Michio Imamura; Kei Morio; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Tomokazu Kawaoka; Shoichi Takahashi; Daiki Miki; Masataka Tsuge; Akira Hiramatsu; Hiroshi Aikata; C Nelson Hayes; Kazuaki Chayama
Journal:  BMC Gastroenterol       Date:  2019-10-24       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.